EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hypersensitivity reaction risk when restarting cenobamate after discontinuation: Insights from a prolonged hospitalized cohort

Marina Feldman iD, Andreas Alexopoulos iD, Juan Bulacio iD, Dileep Nair iD, Vineet Punia iD

Epilepsia Open · 2026-08 · 11 (4) · 1255-1262

DOI: 10.1002/epi4.70288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, online erschienen am 05.06.2026. Verfasst von Marina Feldman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Epilepsy Center, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Carbamates, Chlorophenols, Drug Hypersensitivity. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the risk of hypersensitivity reactions, including dermatological rashes, when cenobamate (CNB) is restarted at maintenance doses after temporary discontinuation.

Methods

We leveraged the natural experiment of long antiseizure medication discontinuation during intracranial EEG evaluation and conducted a retrospective cohort study of these patients at a tertiary epilepsy center who were taking CNB at admission. Clinical data, including duration of interruption, restart dose, and occurrence of dermatologic or hypersensitivity adverse events, were extracted from electronic health records. Patients were followed during hospitalization and for 2 weeks postdischarge.

Results

Thirty‐two patients (53% female; median age 29 years) were included. CNB was withheld for a median of 7 days (IQR 5–8) and restarted at a median dose of 200 mg/day (IQR 193.75–250), including 25% restarted at ≥300 mg/day. Four patients had interruptions ≥10 days. Fourteen patients (44%) had a history of rash. No hypersensitivity reactions attributable to CNB, including rash, were observed during hospitalization or follow‐up. Significance These findings provide the first evidence that short‐term CNB interruptions may not require retitration in previously tolerant patients. This has direct implications for managing nonadherence in routine clinical care. Prospective studies are needed to confirm safety across larger cohorts and longer interruptions. Plain Language Summary Many people with epilepsy miss doses of their seizure medicines, but it is unclear whether cenobamate needs to be slowly restarted after a short break. We studied 32 hospitalized patients who stopped cenobamate for about a week and then restarted their usual dose, and none developed a drug‐related rash or allergic reaction, even those at higher doses or with prior rash history. These findings suggest that short interruptions of cenobamate may be safely restarted without retitration in patients who previously tolerated the medication, though larger studies are needed to confirm this.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsCarbamatesChlorophenolsDrug HypersensitivityEpilepsyHumansFemaleAdultRetrospective StudiesMaleYoung AdultHospitalizationTreatment InterruptionTetrazoles

Stichwörter der Autor:innen

adverse effectsdrug safetyepilepsy monitoring unitmedication adherencerash

Substanzen

AnticonvulsantsCarbamatesCenobamateChlorophenolsTetrazoles

Autor:innen und Institutionen

  • Cleveland Clinic, Epilepsy Center, Cleveland, Ohio, USA.

ORCID-Profile: Marina Feldman, Andreas Alexopoulos, Juan Bulacio, Dileep Nair, Vineet Punia

Zitieren

APA

Feldman, M., Alexopoulos, A., Bulacio, J., Nair, D., & Punia, V. (2026). Hypersensitivity reaction risk when restarting cenobamate after discontinuation: Insights from a prolonged hospitalized cohort. Epilepsia Open, 11(4), 1255-1262. https://doi.org/10.1002/epi4.70288

Vancouver

Feldman M, Alexopoulos A, Bulacio J, Nair D, Punia V. Hypersensitivity reaction risk when restarting cenobamate after discontinuation: Insights from a prolonged hospitalized cohort. Epilepsia Open. 2026;11(4):1255-1262. doi:10.1002/epi4.70288

BibTeX
@article{Feldman2026,
  author = {Feldman, Marina and Alexopoulos, Andreas and Bulacio, Juan and Nair, Dileep and Punia, Vineet},
  title = {Hypersensitivity reaction risk when restarting cenobamate after discontinuation: Insights from a prolonged hospitalized cohort},
  journal = {Epilepsia Open},
  year = {2026},
  volume = {11},
  number = {4},
  pages = {1255--1262},
  doi = {10.1002/epi4.70288}
}
Kostenlos starten →